Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER)

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. 2020. [cited 2020 Sep 5]. Available from: https://goldcopd.org/gold-reports/.
   Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217.
   PubMed Web of Science ®Google Scholar
• Worth H, Buhl R, Criée C-P, et al. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study. Respir Med. 2017;131:77–84. DOI:https://doi.org/10.1016/j.rmed.2017.08.008
   PubMed Web of Science ®Google Scholar
• Vestbo J, Vogelmeier C, Small M, et al. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med. 2014;108(5):729–736. DOI:https://doi.org/10.1016/j.rmed.2014.03.002
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. DOI:https://doi.org/10.1164/rccm.201703-0449OC
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. DOI:https://doi.org/10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. DOI:https://doi.org/10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. DOI:https://doi.org/10.1016/S0140-6736(16)31354-X
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. DOI:https://doi.org/10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, ph 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. DOI:https://doi.org/10.1016/S2213-2600(18)30327-8
   PubMed Web of Science ®Google Scholar
• Yu AP, Guérin A, de Leon DP, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–496. DOI:https://doi.org/10.3111/13696998.2011.594123
   PubMedGoogle Scholar
• Yu AP, Guérin A, de Leon DP, et al. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med. 2011;105(12):1861–1871. DOI:https://doi.org/10.1016/j.rmed.2011.07.001
   PubMed Web of Science ®Google Scholar
• Hillyer EV, Price DB, Chrystyn H, on behalf of the Respiratory Effectiveness Group, Small Airways Study Group, et al. Harmonizing the nomenclature for therapeutic aerosol particle size: a proposal. J Aerosol Med Pulm Drug Deliv. 2018;31(2):111–113. DOI:https://doi.org/10.1089/jamp.2017.1396
   PubMed Web of Science ®Google Scholar
• Braido F, Scichilone N, Lavorini F, et al. Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document. World Allergy Organ J. 2016;9:1–6.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Pedersen S, Usmani OS, et al. Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest. 2017;151(6):1345–1355. DOI:https://doi.org/10.1016/j.chest.2016.07.035
   PubMed Web of Science ®Google Scholar
• Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med. 2012;44(2):146–156. DOI:https://doi.org/10.3109/07853890.2011.585656
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497–1504. DOI:https://doi.org/10.1164/rccm.200410-1414OC
   PubMed Web of Science ®Google Scholar
• LaForce C, Feldman G, Spangenthal S, et al. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEMI study. Int J Chron Obstruct Pulmon Dis. 2016;11:1233–1243.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Stiler TM, Korenblat P, et al. Efficacy and safety of twice-daily glycopyrrolate versus placebo in patients with COPD: The GEM2 Study. J Copd F. 2016;3(2):549–559. DOI:https://doi.org/10.15326/jcopdf.3.2.2015.0157
   PubMedGoogle Scholar
• Edwards D, Berry JJ. The efficiency of simulation-based multiple comparisons. Biometrics. 1987;43(4):913–928.
   PubMed Web of Science ®Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. DOI:https://doi.org/10.1081/copd-200053377
   PubMedGoogle Scholar
• Mahler DA, Witek TJ. The MCID of the Transition Dyspnea Index is a total score of one unit. COPD. 2005;2(1):99–103. DOI:https://doi.org/10.1081/copd-200050666
   PubMedGoogle Scholar
• Arievich H, Overend T, Renard D, et al. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012;12:74.
   PubMed Web of Science ®Google Scholar
• Singh D, Scuri M, Collarini S, et al. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study. COPD. 2017;12:2001–2014. DOI:https://doi.org/10.2147/COPD.S137659
   Google Scholar
• Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106–1114. DOI:https://doi.org/10.1183/09031936.00040712
   PubMed Web of Science ®Google Scholar
• McGarvey L, Morice AH, Smith JA, et al. Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials. BMJ Open Resp Res. 2016;3(1):e000148. DOI:https://doi.org/10.1136/bmjresp-2016-000148
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. DOI:https://doi.org/10.1016/S0140-6736(19)32215-9
   PubMed Web of Science ®Google Scholar